Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss.
The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine.
“The early onset of glycemic improvement, observed as soon as four weeks, reinforces the therapeutic potential of orforglipron as an effective, oral GLP-1 therapy for early type 2 diabetes treatment,” said Dr. Rosenstock.
The pill does not require food/water restrictions, and could be transformative for millions preferring oral medications over injectables.
